Poractant alfa is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada.
- Mechanism
- Curator reviewed
Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli in the lungs, thus stabilizing them against collapse under transpulmonary pressures. A deficiency of pulmonary surfactant in premature infants allows surface tension to increase to the point where sections of lung collapse and respiratory distress syndrome (RDS) develops. Poractant alfa lowers minimum surface tension to less than or equal to 4 mN/m. This compensates for the lack of endogenous surfactant and restores adequate surface activity to the lungs.
- Primary indication
- Poractant alfa is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.Curator reviewed · 1 structured indication
- First approval
- Canada, 2013 · United States, 1999
- Brand names
Resolves to
What you can answer from here — as of July 03, 2026
Which drugs share a target with Poractant alfa, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account